Metraipolis › archive › dc_9ccc6832bb12

Concurrent naxitamab and lorlatinib in a patient with refractory high-risk neuroblastoma: a case report — Europe PMC PMID:41948498

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41948498
DOI
10.3389/fonc.2026.1790294
License (as archived)
solo-consultazione
Archived
2026-11-04T02:43:15.191Z
SHA-256 of the archived text
19d8e787ccc99a44787ca545cbcafe274b9effaf11e3ee1223ea5c2da8b4cb7b
Stable URL of this page
https://metraipolis.com/documento/dc_9ccc6832bb12

How to cite

Concurrent naxitamab and lorlatinib in a patient with refractory high-risk neuroblastoma: a case report — Europe PMC PMID:41948498 — Europe PMC (en), https://europepmc.org/article/MED/41948498 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9ccc6832bb12 (Metraipolis archive dc_9ccc6832bb12, sha256 19d8e787ccc99a44787ca545cbcafe274b9effaf11e3ee1223ea5c2da8b4cb7b)
BibTeX
@misc{dc9ccc6832bb12,
  title = {Concurrent naxitamab and lorlatinib in a patient with refractory high-risk neuroblastoma: a case report — Europe PMC PMID:41948498},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41948498},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9ccc6832bb12; sha256 19d8e787ccc99a44787ca545cbcafe274b9effaf11e3ee1223ea5c2da8b4cb7b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41948498. Agents can read the archived copy with the MCP tool read_document.